Repurposing GLP-1 receptor agonists and novel dual/triple GLP-1, GIP, and glucagon agonists represent promising therapeutic strategies that have shown to be effective in targeting inflammation, tau phosphorylation, synaptic dysfunction, insulin resistance, and oxidative stress
Peptides sold in the research-chemical channel are labeled for laboratory use, are not manufactured to pharmaceutical identity or purity standards, and cannot be assumed to match the trial material in content, dose, or purity
Foundayo is a small-molecule, non-peptide GLP-1 that offers an oral alternative in a treatment space that has largely been dominated by injectables
GLP-1 medications represent one option that may help address biological drivers of appetite under medical supervision, though they work best when combined with healthy lifestyle practices